RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Synthesis of a Radiotracer for Studying s Receptors In Vivo Using PET: (+)-N-[11C]-benzl-N-normetazocine (1S,5S,9S-(+)-cis-2-[11C]-benzyl-2'-hydroxy-5,9-dimethyl-6,7-benzomorphan)
Musachio, J. L., Mathews, W. B., Ravert, H. T., Carroll, F., & Dannals, R. F. (1994). Synthesis of a Radiotracer for Studying s Receptors In Vivo Using PET: (+)-N-[11C]-benzl-N-normetazocine (1S,5S,9S-(+)-cis-2-[11C]-benzyl-2'-hydroxy-5,9-dimethyl-6,7-benzomorphan). Journal of Labelled Compounds and Radiopharmaceuticals, 34(1), 49-57. https://doi.org/10.1002/jlcr.2580340107
(+)‐N‐[11C]‐Benzyl‐N‐normetazocine (1S,5S,9S‐(+)‐cis‐2‐[11C]‐benzyl‐2′‐hydroxy‐5,9‐dimethyl‐6,7‐benzomorphan), a potent and selective ligand for the σ receptor, was prepared by N‐benzylation of (+)‐cis‐N‐normetazocine with [α‐11C]‐benzyl iodide in ethanol using sodium hydrogen carbonate as the proton acceptor. The radiotracer was purified by semi‐preparative reverse‐phase HPLC. The average specific activity was 746 mCi/μmol calculated at end‐of‐synthesis (EOS). The average time of synthesis including formulation was 35 minutes.